Clinical Trials
20
Trial Phases
3 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
- Conditions
- Vaginosis, BacterialVaginal Infection
- Interventions
- Drug: GW05
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2011-07-01
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 255
- Registration Number
- NCT01055106
- Locations
- 🇺🇸
Women's Health Research, Phoenix, Arizona, United States
🇺🇸Precision Trials, Phoenix, Arizona, United States
🇺🇸NEA Women's Clinic, Jonesboro, Arkansas, United States
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 247
- Registration Number
- NCT00894647
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Spencer Dermatology & Skin Surgery Center, St. Petersberg, Florida, United States
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
- Conditions
- Genital Warts
- Interventions
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 511
- Registration Number
- NCT00735462
- Locations
- 🇺🇸
NEA Clinic, Jonesboro, Arkansas, United States
🇺🇸Northern Claifornia Research, Carmichael, California, United States
🇺🇸California State University - Chico, Chico, California, United States
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
- Conditions
- Genital Warts
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 470
- Registration Number
- NCT00674739
- Locations
- 🇺🇸
WILMAX Clinical Research, Mobile, Alabama, United States
🇺🇸Montgomery Women's Health Associates, Montgomery, Alabama, United States
🇺🇸Women's Health Research, Phoenix, Arizona, United States
Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year
- Conditions
- Actinic Keratoses
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2010-07-20
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 179
- Registration Number
- NCT00668733
- Prev
- 1
- 2
- 3
- 4
- Next